Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia

European Journal of Pharmacology

Volumn 682, Issue 1-3, 2012, Pages 1-11

  De Bartolomeis, Andrea ^a   Sarappa, Chiara ^a   Magara, Salvatore ^a,b   Iasevoli, Felice ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

AMPAkine; Glycine; Memantine; mGluR; Psychosis; Sarcosine

Indexed keywords

2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ADX 47273; AMPA RECEPTOR; AMPAKINE DERIVATIVE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CX 717; CYCLOSERINE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; GLYCINE TRANSPORTER INHIBITOR; MEMANTINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; MOLINDONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RG 1678; RISPERIDONE; SARCOSINE; SSR 103800; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALZHEIMER DISEASE; CATATONIC SCHIZOPHRENIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; EXCITOTOXICITY; HUMAN; MONOTHERAPY; NEGATIVE SYNDROME; NONHUMAN; OPEN FIELD TEST; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; REVIEW; SCHIZOPHRENIA; SYMPTOM; TREATMENT RESPONSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; GLUTAMIC ACID; HUMANS; MOLECULAR TARGETED THERAPY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84859106184     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.02.033     Document Type: Review

References (130)

1. T. Adage, A.C. Trillat, A. Quattropani, D. Perrin, L. Cavarec, J. Shaw, O. Guerassimenko, C. Giachetti, B. Greco, I. Chumakov, S. Halazy, A. Roach, and P. Zaratin In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties Eur. Neuropsychopharmacol. 18 2008 200 214
2. D. Alberati, J.L. Moreau, J. Lengyel, N. Hauser, R. Mory, E. Borroni, E. Pinard, F. Knoflach, G. Schlotterbeck, D. Hainzl, and J.G. Wettstein Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia Neuropharmacology 62 2012 1152 1161
3. J. Arnt, T. Skarsfeldt, and J. Hyttel Differentiation of classical and novel antipsychotics using animal models Int. Clin. Psychopharmacol. 12 Suppl 1 1997 S9 S17
4. H. Awad, G.W. Hubert, Y. Smith, A.I. Levey, and P.J. Conn Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus J. Neurosci. 20 2000 7871 7879
5. S.P. Banerjee, L.G. Zuck, E. Yablonsky-Alter, and T.I. Lidsky Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia Neuroreport 6 1995 2500 2504
6. C.A. Barnes, W. Danysz, and C.G. Parsons Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats Eur. J. Neurosci. 8 1996 565 571
7. F. Bergeron, A. Otto, P. Blache, R. Day, L. Denoroy, R. Brandsch, and D. Bataille Molecular cloning and tissue distribution of rat sarcosine dehydrogenase Eur. J. Biochem. 257 1998 556 561
8. M.D. Black, G.B. Varty, M. Arad, S. Barak, A. De Levie, D. Boulay, P. Pichat, G. Griebel, and I. Weiner Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat Psychopharmacology (Berl) 202 2009 385 396
9. D. Boulay, O. Bergis, P. Avenet, and G. Griebel The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice Neuropsychopharmacology 35 2010 416 427
10. R.W. Buchanan, D.C. Javitt, S.R. Marder, N.R. Schooler, J.M. Gold, R.P. McMahon, U. Heresco-Levy, and W.T. Carpenter The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments Am. J. Psychiatry 164 2007 1593 1602
11. J. Camarasa, J.M. Marimon, T. Rodrigo, E. Escubedo, and D. Pubill Memantine prevents the cognitive impairment induced by 3,4- methylenedioxymethamphetamine in rats Eur. J. Pharmacol. 589 2008 132 139
12. S.S. Carpenter, A.D. Hatchett, and M.A. Fuller Catatonic schizophrenia and the use of memantine Ann. Pharmacother. 40 2006 344 346
13. N.G. Cascella, F. Macciardi, C. Cavallini, and E. Smeraldi d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study J. Neural. Transm. Gen. Sect. 95 1994 105 111
14. H.H. Chen, A. Stoker, and A. Markou The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice Psychopharmacology (Berl) 209 2010 343 350
15. R. Chiusaroli, P. Garofalo, S. Espinoza, E. Neri, G. Caselli, and M. Lanza Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat Pharmacol. Res. 61 2010 430 436
16. I. Chumakov, M. Blumenfeld, O. Guerassimenko, L. Cavarec, M. Palicio, H. Abderrahim, L. Bougueleret, C. Barry, H. Tanaka, P. La Rosa, A. Puech, N. Tahri, A. Cohen-Akenine, S. Delabrosse, S. Lissarrague, F.P. Picard, K. Maurice, L. Essioux, P. Millasseau, P. Grel, V. Debailleul, A.M. Simon, D. Caterina, I. Dufaure, K. Malekzadeh, M. Belova, J.J. Luan, M. Bouillot, J.L. Sambucy, G. Primas, M. Saumier, N. Boubkiri, S. Martin-Saumier, M. Nasroune, H. Peixoto, A. Delaye, V. Pinchot, M. Bastucci, S. Guillou, M. Chevillon, R. Sainz-Fuertes, S. Meguenni, J. Aurich-Costa, D. Cherif, A. Gimalac, C. Van Duijn, D. Gauvreau, G. Ouellette, I. Fortier, J. Raelson, T. Sherbatich, N. Riazanskaia, E. Rogaev, P. Raeymaekers, J. Aerssens, F. Konings, W. Luyten, F. Macciardi, P.C. Sham, R.E. Straub, D.R. Weinberger, N. Cohen, and D. Cohen Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia Proc. Natl. Acad. Sci. U. S. A. 99 2002 13675 13680
17. J. Costa, E. Khaled, J. Sramek, W. Bunney Jr., and S.G. Potkin An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics J. Clin. Psychopharmacol. 10 1990 71 72
18. R. Dall'Olio, and O. Gandolfi The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of D1 and D2 dopamine receptor blockers in the rat Psychopharmacology (Berl) 110 1993 165 168
19. R. Dall'Olio, R. Rimondini, F. Locchi, M. Voltattorni, and O. Gandolfi An ionotropic but not a metabotropic glutamate agonist potentiates the pharmacological effects of olanzapine in the rat Behav. Pharmacol. 16 2005 635 642
20. G. Dannhardt, and B.K. Kohl The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications Curr. Med. Chem. 5 1998 253 263
21. W. Danysz, and C.G. Parsons Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications Pharmacol. Rev. 50 1998 597 664
22. D. de Lucena, B.S. Fernandes, M. Berk, S. Dodd, D.W. Medeiros, M. Pedrini, M. Kunz, F.A. Gomes, L.F. Giglio, M.I. Lobato, P.S. Belmonte-de-Abreu, and C.S. Gama Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine J. Clin. Psychiatry 70 2009 1416 1423
23. J.F. Deakin, and M.D. Simpson A two-process theory of schizophrenia: evidence from studies in post-mortem brain J. Psychiatr. Res. 31 1997 277 295
24. J.F. Deakin, P. Slater, M.D. Simpson, A.C. Gilchrist, W.J. Skan, M.C. Royston, G.P. Reynolds, and A.J. Cross Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia J. Neurochem. 52 1989 1781 1786
25. P. Diaz, S. Bhaskara, S.M. Dursun, and B. Deakin Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results J. Clin. Psychopharmacol. 25 2005 277 278
26. M. Dozmorov, R. Li, A.K. Abbas, F. Hellberg, C. Farre, F.S. Huang, B. Jilderos, and H. Wigstrom Contribution of AMPA and NMDA receptors to early and late phases of LTP in hippocampal slices Neurosci. Res. 55 2006 182 188
27. S.M. Dravid, P.B. Burger, A. Prakash, M.T. Geballe, R. Yadav, P. Le, K. Vellano, J.P. Snyder, and S.F. Traynelis Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors J. Neurosci. 30 2010 2741 2754
28. A.E. Evins, E. Amico, T.A. Posever, R. Toker, and D.C. Goff D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia Schizophr. Res. 56 2002 19 23
29. N.B. Farber, J.W. Newcomer, and J.W. Olney Glycine agonists: what can they teach us about schizophrenia? Arch. Gen. Psychiatry 56 1999 13 17
30. E.J. Fletcher, and J.F. MacDonald Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones Eur. J. Pharmacol. 235 1993 291 295
31. X.M. Gao, K. Sakai, R.C. Roberts, R.R. Conley, B. Dean, and C.A. Tamminga Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia Am. J. Psychiatry 157 2000 1141 1149
32. D.C. Goff, G. Tsai, D.S. Manoach, and J.T. Coyle Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia Am. J. Psychiatry 152 1995 1213 1215
33. D.C. Goff, D.C. Henderson, A.E. Evins, and E. Amico A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia Biol. Psychiatry 45 1999 512 514
34. D.C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D.A. Schoenfeld, D.L. Hayden, R. McCarley, and J.T. Coyle A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch. Gen. Psychiatry 56 1999 21 27
35. D.C. Goff, L. Leahy, I. Berman, T. Posever, L. Herz, A.C. Leon, S.A. Johnson, and G. Lynch A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia J. Clin. Psychopharmacol. 21 2001 484 487
36. D.C. Goff, C. Cather, J.D. Gottlieb, A.E. Evins, J. Walsh, L. Raeke, M.W. Otto, D. Schoenfeld, and M.F. Green Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study Schizophr. Res. 106 2008 320 327
37. D.C. Goff, J.S. Lamberti, A.C. Leon, M.F. Green, A.L. Miller, J. Patel, T. Manschreck, O. Freudenreich, and S.A. Johnson A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia Neuropsychopharmacology 33 2008 465 472
38. L. Gray, M. van den Buuse, E. Scarr, B. Dean, and A.J. Hannan Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation Int. J. Neuropsychopharmacol. 12 2009 45 60
39. R.E. Hampson, G. Rogers, G. Lynch, and S.A. Deadwyler Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance J. Neurosci. 18 1998 2740 2747
40. K. Hashimoto Novel Therapeutic Drugs for Neuropsychiatric Disorders Open Med. Chem. J. 4 2010 1
41. K. Hashimoto Glycine transporter-1: a new potential therapeutic target for schizophrenia Curr. Pharm. Des. 17 2011 112 120
42. K. Hashimoto, Y. Fujita, T. Ishima, S. Chaki, and M. Iyo Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine Eur. Neuropsychopharmacol. 18 2008 414 421
43. K. Hashimoto, Y. Fujita, M. Horio, S. Kunitachi, M. Iyo, D. Ferraris, and T. Tsukamoto Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine Biol. Psychiatry 65 2009 1103 1106
44. U. Heresco-Levy, and D.C. Javitt Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis Schizophr. Res. 66 2004 89 96
45. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, A. Horowitz, and D. Kelly Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia Br. J. Psychiatry 169 1996 610 617
46. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch. Gen. Psychiatry 56 1999 29 36
47. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D.C. Javitt Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia Am. J. Psychiatry 159 2002 480 482
48. U. Heresco-Levy, D.C. Javitt, R. Ebstein, A. Vass, P. Lichtenberg, G. Bar, S. Catinari, and M. Ermilov D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia Biol. Psychiatry 57 2005 577 585
49. M. Horio, Y. Fujita, T. Ishima, M. Iyo, D. Ferraris, T. Tsukamoto, and K. Hashimoto Effects of D-Amino Acid Oxidase Inhibitor on the Extracellular D-Alanine Levels and the Efficacy of D-Alanine on Dizocilpine-Induced Prepulse Inhibition Deficits in Mice Open Clin. Chem. J. 2 2009 16 21
50. F. Iasevoli, D. Polese, A. Ambesi-Impiombato, G. Muscettola, and A. de Bartolomeis Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis Neurosci. Lett. 416 2007 1 5
51. F. Iasevoli, C. Tomasetti, A. Ambesi-Impiombato, G. Muscettola, and A. de Bartolomeis Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action Prog. Neuropsychopharmacol. Biol. Psychiatry 33 2009 813 821
52. F. Iasevoli, C. Tomasetti, F. Marmo, D. Bravi, J. Arnt, and A. de Bartolomeis Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole Psychopharmacology (Berl) 212 2010 329 344
53. M. Ingvar, J. Ambros-Ingerson, M. Davis, R. Granger, M. Kessler, G.A. Rogers, R.S. Schehr, and G. Lynch Enhancement by an ampakine of memory encoding in humans Exp. Neurol. 146 1997 553 559
54. D.C. Javitt, A. Balla, H. Sershen, and A. Lajtha A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors Biol. Psychiatry 45 1999 668 679
55. D.C. Javitt, G. Silipo, A. Cienfuegos, A.M. Shelley, N. Bark, M. Park, J.P. Lindenmayer, R. Suckow, and S.R. Zukin Adjunctive high-dose glycine in the treatment of schizophrenia Int. J. Neuropsychopharmacol. 4 2001 385 391
56. D.C. Javitt, A. Balla, S. Burch, R. Suckow, S. Xie, and H. Sershen Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists Neuropsychopharmacology 29 2004 300 307
57. D.C. Javitt, L. Duncan, A. Balla, and H. Sershen Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action Mol. Psychiatry 10 2005 275 287
58. J.W. Johnson, and S.E. Kotermanski Mechanism of action of memantine Curr. Opin. Pharmacol. 6 2006 61 67
59. S.A. Johnson, N.T. Luu, T.A. Herbst, R. Knapp, D. Lutz, A. Arai, G.A. Rogers, and G. Lynch Synergistic interactions between ampakines and antipsychotic drugs J. Pharmacol. Exp. Ther. 289 1999 392 397
60. J.T. Kantrowitz, and D.C. Javitt N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res. Bull. 83 2010 108 121
61. S. Kapur, and G. Remington Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia Annu. Rev. Med. 52 2001 503 517
62. J. Karasawa, K. Hashimoto, and S. Chaki D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats Behav. Brain Res 186 2008 78 83
63. G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 313 2005 199 206
64. R.J. Knapp, R. Goldenberg, C. Shuck, A. Cecil, J. Watkins, C. Miller, G. Crites, and E. Malatynska Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model Eur. J. Pharmacol. 440 2002 27 35
65. S.E. Kotermanski, J.T. Wood, and J.W. Johnson Memantine binding to a superficial site on NMDA receptors contributes to partial trapping J. Physiol. 587 2009 4589 4604
66. A. Krivoy, A. Weizman, L. Laor, N. Hellinger, Z. Zemishlany, and T. Fischel Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study Eur. Neuropsychopharmacol. 18 2008 117 121
67. J.H. Krystal, D.C. D'Souza, D. Mathalon, E. Perry, A. Belger, and R. Hoffman NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development Psychopharmacology (Berl) 169 2003 215 233
68. V. Labrie, T. Lipina, and J.C. Roder Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia Psychopharmacology (Berl) 200 2008 217 230
69. V. Labrie, S.J. Clapcote, and J.C. Roder Mutant mice with reduced NMDA-NR1 glycine affinity or lack of D-amino acid oxidase function exhibit altered anxiety-like behaviors Pharmacol. Biochem. Behav. 91 2009 610 620
70. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, and C.A. Tamminga Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 25 2001 455 467
71. H.Y. Lane, Y.C. Chang, Y.C. Liu, C.C. Chiu, and G.E. Tsai Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study Arch. Gen. Psychiatry 62 2005 1196 1204
72. H.Y. Lane, C.L. Huang, P.L. Wu, Y.C. Liu, Y.C. Chang, P.Y. Lin, P.W. Chen, and G. Tsai Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia Biol. Psychiatry 60 2006 645 649
73. H.Y. Lane, Y.C. Liu, C.L. Huang, Y.C. Chang, C.H. Liau, C.H. Perng, and G.E. Tsai Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study Biol. Psychiatry 63 2008 9 12
74. H.Y. Lane, C.H. Lin, Y.J. Huang, C.H. Liao, Y.C. Chang, and G.E. Tsai A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia Int. J. Neuropsychopharmacol. 13 2010 451 460
75. M. Lanza, C. Bonnafous, S. Colombo, L. Revel, and F. Makovec Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex Neuropharmacology 36 1997 1057 1064
76. E. Leiderman, I. Zylberman, S.R. Zukin, T.B. Cooper, and D.C. Javitt Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial Biol. Psychiatry 39 1996 213 215
77. S. Leucht, K. Wahlbeck, J. Hamann, and W. Kissling New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 361 2003 1581 1589
78. S. Leucht, S. Heres, W. Kissling, and J.M. Davis Evidence-based pharmacotherapy of schizophrenia Int. J. Neuropsychopharmacol. 14 2011 269 284
79. J.A. Lieberman, K. Papadakis, J. Csernansky, R. Litman, J. Volavka, X.D. Jia, and A. Gage A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia Neuropsychopharmacology 34 2009 1322 1329
80. J.P. Lindenmayer Treatment refractory schizophrenia Psychiatr. Q. 71 2000 373 384
81. T. Lipina, V. Labrie, I. Weiner, and J. Roder Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia Psychopharmacology (Berl) 179 2005 54 67
82. F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P.J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, D. Smith, M. Olsen, E. Kouranova, M. Lai, F. Pruthi, C. Pulicicchio, M. Day, A. Gilbert, M.H. Pausch, N.J. Brandon, C.E. Beyer, T.A. Comery, S. Logue, S. Rosenzweig-Lipson, and K.L. Marquis ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol- 5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Ther. 327 2008 827 839
83. S. Marenco, M.F. Egan, T.E. Goldberg, M.B. Knable, R.K. McClure, G. Winterer, and D.R. Weinberger Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series Schizophr. Res. 57 2002 221 226
84. L. McCoy, and E.K. Richfield Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain Neurosci. Lett. 213 1996 137 141
85. J.H. Meador-Woodruff, and D.J. Healy Glutamate receptor expression in schizophrenic brain Brain Res. Brain Res. Rev. 31 2000 288 294
86. M. Melone, L. Vitellaro-Zuccarello, A. Vallejo-Illarramendi, A. Perez-Samartin, C. Matute, A. Cozzi, D.E. Pellegrini-Giampietro, J.D. Rothstein, and F. Conti The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine Mol. Psychiatry 6 2001 380 386
87. K. Miya, R. Inoue, Y. Takata, M. Abe, R. Natsume, K. Sakimura, K. Hongou, T. Miyawaki, and H. Mori Serine racemase is predominantly localized in neurons in mouse brain J. Comp. Neurol. 510 2008 641 654
88. T. Nishikawa, M. Takashima, and M. Toru Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia Neurosci. Lett. 40 1983 245 250
89. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch. Gen. Psychiatry 52 1995 998 1007
90. C.K. Olsen, M. Kreilgaard, and M. Didriksen Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats Pharmacol. Biochem. Behav. 84 2006 259 265
91. C.G. Parsons, and K. Gilling Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker Methods Mol. Biol. 403 2007 15 36
92. C.G. Parsons, W. Danysz, and G. Quack Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data Neuropharmacology 38 1999 735 767
93. D. Polese, A.A. de Serpis, A. Ambesi-Impiombato, G. Muscettola, and A. de Bartolomeis Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine Neuropsychopharmacology 27 2002 906 913
94. L.J. Porrino, J.B. Daunais, G.A. Rogers, R.E. Hampson, and S.A. Deadwyler Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates PLoS Biol. 3 2005 e299
95. S.G. Potkin, Y. Jin, B.G. Bunney, J. Costa, and B. Gulasekaram Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia Am. J. Psychiatry 156 1999 145 147
96. G.S. Rands Memantine as a neuroprotective treatment in schizophrenia Br. J. Psychiatry 186 2005 77 author reply 77-78
97. A.L. Rodriguez, M.D. Grier, C.K. Jones, E.J. Herman, A.S. Kane, R.L. Smith, R. Williams, Y. Zhou, J.E. Marlo, E.L. Days, T.N. Blatt, S. Jadhav, U.N. Menon, P.N. Vinson, J.M. Rook, S.R. Stauffer, C.M. Niswender, C.W. Lindsley, C.D. Weaver, and P.J. Conn Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol. Pharmacol. 78 2010 1105 1123
98. R.B. Rosse, S.K. Theut, M. Banay-Schwartz, M. Leighton, E. Scarcella, C.G. Cohen, and S.I. Deutsch Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study Clin. Neuropharmacol. 12 1989 416 424
99. R.B. Rosse, M. Fay-McCarthy, K. Kendrick, R.E. Davis, and S.I. Deutsch D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia Clin. Neuropharmacol. 19 1996 444 450
100. M.J. Schell, M.E. Molliver, and S.H. Snyder D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release Proc. Natl. Acad. Sci. U. S. A. 92 1995 3948 3952
101. C. Schlumberger, M. Pietraszek, A. Gravius, K.U. Klein, S. Greco, L. More, and W. Danysz Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity Eur. J. Pharmacol. 623 2009 73 83
102. C. Schlumberger, M. Pietraszek, A. Gravius, and W. Danysz Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia Pharmacol. Biochem. Behav. 95 2010 23 30
103. H.P. Schmitt On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease Med. Hypotheses 65 2005 259 265
104. L. Schwieler, K.R. Linderholm, L.K. Nilsson-Todd, S. Erhardt, and G. Engberg Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area Life Sci. 83 2008 170 175
105. A. Sheinin, S. Shavit, and M. Benveniste Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine Neuropharmacology 41 2001 151 158
106. T. Shimazaki, A. Kaku, and S. Chaki D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats Psychopharmacology (Berl) 209 2010 263 270
107. W.D. Shipe, S.E. Wolkenberg, D.L. Williams Jr., and C.W. Lindsley Recent advances in positive allosteric modulators of metabotropic glutamate receptors Curr. Opin. Drug Discov. Devel. 8 2005 449 457
108. P. Singer, J. Feldon, and B.K. Yee The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice Psychopharmacology (Berl) 202 2009 371 384
109. R.B. Sleeper Antipsychotic dose-sparing effect with addition of memantine Ann. Pharmacother. 39 2005 1573 1576
110. S.M. Smith, J.M. Uslaner, L. Yao, C.M. Mullins, N.O. Surles, S.L. Huszar, C.H. McNaughton, D.M. Pascarella, M. Kandebo, R.M. Hinchliffe, T. Sparey, N.J. Brandon, B. Jones, S. Venkatraman, M.B. Young, N. Sachs, M.A. Jacobson, and P.H. Hutson The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine J. Pharmacol. Exp. Ther. 328 2009 921 930
111. N. Spear, R.A. Gadient, D.E. Wilkins, M. Do, J.S. Smith, K.L. Zeller, P. Schroeder, M. Zhang, J. Arora, and V. Chhajlani Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator Eur. J. Pharmacol. 659 2011 146 154
112. H. Stefansson, E. Sigurdsson, V. Steinthorsdottir, S. Bjornsdottir, T. Sigmundsson, S. Ghosh, J. Brynjolfsson, S. Gunnarsdottir, O. Ivarsson, T.T. Chou, O. Hjaltason, B. Birgisdottir, H. Jonsson, V.G. Gudnadottir, E. Gudmundsdottir, A. Bjornsson, B. Ingvarsson, A. Ingason, S. Sigfusson, H. Hardardottir, R.P. Harvey, D. Lai, M. Zhou, D. Brunner, V. Mutel, A. Gonzalo, G. Lemke, J. Sainz, G. Johannesson, T. Andresson, D. Gudbjartsson, A. Manolescu, M.L. Frigge, M.E. Gurney, A. Kong, J.R. Gulcher, H. Petursson, and K. Stefansson Neuregulin 1 and susceptibility to schizophrenia Am. J. Hum. Genet. 71 2002 877 892
113. V. Suppiramaniam, B.A. Bahr, S. Sinnarajah, K. Owens, G. Rogers, S. Yilma, and V. Vodyanoy Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors Synapse 40 2001 154 158
114. N.R. Swerdlow, D.P. van Bergeijk, F. Bergsma, E. Weber, and J. Talledo The effects of memantine on prepulse inhibition Neuropsychopharmacology 34 2009 1854 1864
115. Y. Tanii, T. Nishikawa, A. Hashimoto, and K. Takahashi Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat J. Pharmacol. Exp. Ther. 269 1994 1040 1048
116. C. Thomas, B.T. Carroll, R.T. Maley, K. Jayanti, and A. Koduri Memantine and catatonic schizophrenia Am. J. Psychiatry 162 2005 626
117. G.E. Tsai, and P.Y. Lin Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis Curr. Pharm. Des. 16 2010 522 537
118. G. Tsai, P. Yang, L.C. Chung, N. Lange, and J.T. Coyle D-serine added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 44 1998 1081 1089
119. G.E. Tsai, P. Yang, L.C. Chung, I.C. Tsai, C.W. Tsai, and J.T. Coyle D-serine added to clozapine for the treatment of schizophrenia Am. J. Psychiatry 156 1999 1822 1825
120. G. Tsai, H.Y. Lane, P. Yang, M.Y. Chong, and N. Lange Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 55 2004 452 456
121. G. Tsai, R.J. Ralph-Williams, M. Martina, R. Bergeron, J. Berger-Sweeney, K.S. Dunham, Z. Jiang, S.B. Caine, and J.T. Coyle Gene knockout of glycine transporter 1: characterization of the behavioral phenotype Proc. Natl. Acad. Sci. U. S. A. 101 2004 8485 8490
122. G.E. Tsai, P. Yang, Y.C. Chang, and M.Y. Chong D-alanine added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 59 2006 230 234
123. H.J. Tuominen, J. Tiihonen, and K. Wahlbeck Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis Schizophr. Res. 72 2005 225 234
124. D. Van Dam, and P.P. De Deyn Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model Eur. Neuropsychopharmacol. 16 2006 59 69
125. D. Van Dam, D. Abramowski, M. Staufenbiel, and P.P. De Deyn Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model Psychopharmacology (Berl) 180 2005 177 190
126. J.D. Vardigan, S.L. Huszar, C.H. McNaughton, P.H. Hutson, and J.M. Uslaner MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol. Biochem. Behav. 95 2010 223 229
127. E. Wezenberg, R.J. Verkes, G.S. Ruigt, W. Hulstijn, and B.G. Sabbe Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers Neuropsychopharmacology 32 2007 1272 1283
128. C.B. Willmore, K.L. LaVecchia, and J.L. Wiley NMDA antagonists produce site-selective impairment of accuracy in a delayed nonmatch-to-sample task in rats Neuropharmacology 41 2001 916 927
129. S.Y. Yang, C.J. Hong, Y.H. Huang, and S.J. Tsai The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats Neurosci. Lett. 469 2010 127 130
130. W. Zajaczkowski, G. Quack, and W. Danysz Infusion of (+) -MK-801 and memantine - contrasting effects on radial maze learning in rats with entorhinal cortex lesion Eur. J. Pharmacol. 296 1996 239 246